Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by:
First received: October 29, 2004
Last updated: September 10, 2010
Last verified: September 2007
The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients|
Resource links provided by NLM:
Further study details as provided by Bristol-Myers Squibb:
Primary Outcome Measures:
- The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar
|Study Start Date:||May 2004|
|Study Completion Date:||May 2006|
|Primary Completion Date:||May 2006 (Final data collection date for primary outcome measure)|
Contacts and Locations